Dexamphetamine
Phase 2Small molecule
Dexamphetamine is one of 11 small molecule programs targeting Cocaine Use Disorder. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Cocaine Use Disorder
#DrugCompanyPhaseTrials
1Rocaltrol
Jazz PharmaceuticalsApproved
Actos
TakedaApproved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Pitocin
RRetrophin
Approved
Ozempic
Novo NordiskPhase 2
Buspar
Bristol-Myers SquibbPreclinical
Psilocybin
COMPASS PathwaysPhase 1
D-Amphetamine
NNoven Pharmaceuticals, Inc.
Phase 2
Dexamphetamine
TThe Netherlands Cancer Institute
Phase 2
Clavulanic Acid
TTemple University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tics1 trial
Cocaine Use Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexamphetamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TThe Netherlands Cancer Institute